GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.37
+0.18 (+0.45%)
At close: 4:01PM EDT

40.53 +0.16 (0.40%)
Pre-Market: 4:23AM EDT

Stock chart is not supported by your current browser
Previous Close40.19
Open40.32
Bid0.00 x 3000
Ask40.56 x 3100
Day's Range40.22 - 40.47
52 Week Range36.41 - 42.47
Volume1,712,502
Avg. Volume2,330,982
Market Cap100.54B
Beta (3Y Monthly)0.55
PE Ratio (TTM)40.70
EPS (TTM)0.99
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.86 (4.60%)
Ex-Dividend Date2019-08-08
1y Target Est45.33
Trade prices are not sourced from all markets
  • 3 Large-Cap Stocks With High Dividend Yields
    GuruFocus.com

    3 Large-Cap Stocks With High Dividend Yields

    GlaxoSmithKline tops the list Continue reading...

  • Better Buy: Eli Lilly vs. GlaxoSmithKline
    Motley Fool

    Better Buy: Eli Lilly vs. GlaxoSmithKline

    Which stock wins in this big-pharma matchup?

  • Ionis Pharmaceuticals Looks to Partners to Pay the Bills
    Motley Fool

    Ionis Pharmaceuticals Looks to Partners to Pay the Bills

    Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.

  • Should Value Investors Consider GlaxoSmithKline (GSK) Stock?
    Zacks

    Should Value Investors Consider GlaxoSmithKline (GSK) Stock?

    Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

  • GSK's new pharma president carries Merck, Pfizer experience
    American City Business Journals

    GSK's new pharma president carries Merck, Pfizer experience

    With the change of leadership for GSK's pharmaceutical business, the Triangle won't necessarily be losing its GSK leader.

  • AnaptysBio Prepares for a Potential Gear Shift
    Motley Fool

    AnaptysBio Prepares for a Potential Gear Shift

    During the second quarter, the company upgraded the safety net under its lead candidate.

  • Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
    Zacks

    Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

    Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

  • Kahn Brothers' Top 6 Buys in the 2nd Quarter
    GuruFocus.com

    Kahn Brothers' Top 6 Buys in the 2nd Quarter

    Firm of the late Irving Kahn releases portfolio, top buy is Merck Continue reading...

  • Local companies impacted by trade war-fueled stock market decline
    American City Business Journals

    Local companies impacted by trade war-fueled stock market decline

    Among the Philadelphia region’s largest 20 publicly traded companies, three in the chemical industry experienced the biggest dips in midday trading.

  • It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend
    Simply Wall St.

    It Might Be Better To Avoid GlaxoSmithKline plc's (LON:GSK) Upcoming 1.1% Dividend

    GlaxoSmithKline plc (LON:GSK) is about to trade ex-dividend in the next 2 days. You can purchase shares before the 8th...

  • Thomson Reuters StreetEvents

    Edited Transcript of GSK.L earnings conference call or presentation 24-Jul-19 1:00pm GMT

    Q2 2019 GlaxoSmithKline PLC Earnings Call

  • Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates
    Zacks

    Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates

    Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.

  • Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
    Zacks

    Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

    AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

  • Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
    Zacks

    Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates

    Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.

  • GSK, Pfizer complete deal to combine consumer health brands
    American City Business Journals

    GSK, Pfizer complete deal to combine consumer health brands

    Under the terms of the agreement, GSK will own 68% of the consumer health joint venture and Pifzer will own the remaining 32%.

  • Benzinga

    The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 1) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Odonate ...

  • Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
    Zacks

    Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised

    Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.

  • Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
    Zacks

    Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer

    Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.

  • Moody's

    Pharmacia Corporation (Old Monsanto) -- Moody's reviews Pfizer's A1 rating for downgrade; affirms P-1 rating

    Moody's Investors Service ("Moody's") placed the A1 senior unsecured long-term rating of Pfizer Inc. ("Pfizer") under review for downgrade. At the same time, Moody's affirmed Pfizer's Prime-1 commercial paper rating.

  • Top 5 Dividend Stocks in the FTSE for 2018
    Investopedia

    Top 5 Dividend Stocks in the FTSE for 2018

    The five top dividend payers from the FTSE 100.

  • Zacks

    Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan

    Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.

  • 3 Healthcare Stocks With Rising Expectations
    Motley Fool

    3 Healthcare Stocks With Rising Expectations

    It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.

  • Pfizer-Mylan Generic Giant Solves Two Problems With One Deal
    Bloomberg

    Pfizer-Mylan Generic Giant Solves Two Problems With One Deal

    (Bloomberg Opinion) -- The merger of Pfizer Inc.'s off-patent drug business with struggling specialty drugmaker Mylan Inc., announced early Monday morning, should come as a relief for investors on both sides of the transaction. Analysts have been clamoring for Pfizer to split off its Upjohn division focused on legacy drugs from its core prescription-drug operations so the drug giant could sharpen its focus on the higher-margin innovative business. This deal is a chance for CEO Albert Bourla to finally make the separation. And while Mylan holders may look back wistfully at Teva Pharmaceuticals Industry Ltd.’s  $40 billion buyout offer in 2015 – this merger doesn’t offer the same type of immediate return – the deal with Pfizer gives them a 43% stake in a stronger company and will free Mylan’s assets from a management team that has had a calamitous recent run.Pfizer’s slim-down started with the highly successful spinoff of its animal health unit in 2013 and continued in December when it formed a consumer joint venture with GlaxoSmithKline PLC. The company should reap benefits from completing its journey. In its pre-deal form, Pfizer risked years of sluggish growth from declining sales of older drugs. Separating those products will flatter the revenue growth of the company’s newer medicines, and could have the same effect on its valuation.  Pfizer is raising $12 billion in debt that the new company will carry, and keeping the cash. The deal will strengthen Pfizer’s balance sheet and help the company further bolster its roster of novel treatments. The Mylan combination is an excellent way to help Upjohn succeed on its own, and could boost the return on a split Pfizer would likely have pursued anyway. The specialty and generic drug business is brutally competitive, and pricing pressure in the U.S. has squashed profitability for the entire sector. That’s one reason Mylan comes so cheap: The company was worth $25 billion just last year but had a market cap below $10 billion before Monday's announcement. Scale will help the new business push back on pricing, and its broad lineup of products and geographic reach will also help it stand out. The combined company will be less levered than stand-alone Mylan and is expected to generate more than $4 billion in annual free cash flow. All of that makes a strong case in favor of this deal for Mylan investors. The most significant point in its favor, however, might be the planned departure of CEO Heather Bresch, who will retire when the deal closes. She has played a starring role alongside pricing pressure in shrinking the company’s valuation, to the point where Mylan felt compelled to consider its strategic options.Her tenure has brought price-fixing investigations, congressional inquiries into price increases for life-saving EpiPens, delays for crucial products, and repeated earnings misses. She further tarnished Mylan's reputation by investing in coal to lower its tax bill while simultaneously developing asthma medication, collecting rich paychecks as its share price plunged, and enacting shareholder-unfriendly corporate governance.A leadership change should help the market refocus on the good parts of the company, including a valuable international business. Pfizer veteran Michael Goettler will pilot the new company. It would be hard for him to be anything but an improvement. The deal removes a strategic cloud over Pfizer and a management miasma from Mylan. Investors are likely to enjoy the better weather. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.